SG11202100834SA - Use of lc-ms/ms to quantitate protein biomarkers - Google Patents

Use of lc-ms/ms to quantitate protein biomarkers

Info

Publication number
SG11202100834SA
SG11202100834SA SG11202100834SA SG11202100834SA SG11202100834SA SG 11202100834S A SG11202100834S A SG 11202100834SA SG 11202100834S A SG11202100834S A SG 11202100834SA SG 11202100834S A SG11202100834S A SG 11202100834SA SG 11202100834S A SG11202100834S A SG 11202100834SA
Authority
SG
Singapore
Prior art keywords
protein biomarkers
quantitate protein
quantitate
biomarkers
protein
Prior art date
Application number
SG11202100834SA
Other languages
English (en)
Inventor
Sook Yen E
Haibo Qiu
Ning Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202100834SA publication Critical patent/SG11202100834SA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • G01N33/6851Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
SG11202100834SA 2018-08-08 2019-08-07 Use of lc-ms/ms to quantitate protein biomarkers SG11202100834SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862715973P 2018-08-08 2018-08-08
PCT/US2019/045494 WO2020033537A1 (en) 2018-08-08 2019-08-07 Use of lc-ms/ms to quantitate protein biomarkers

Publications (1)

Publication Number Publication Date
SG11202100834SA true SG11202100834SA (en) 2021-02-25

Family

ID=67809655

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100834SA SG11202100834SA (en) 2018-08-08 2019-08-07 Use of lc-ms/ms to quantitate protein biomarkers

Country Status (13)

Country Link
US (2) US11592449B2 (ja)
EP (1) EP3833775A1 (ja)
JP (2) JP7419340B2 (ja)
KR (1) KR20210043589A (ja)
CN (1) CN112888793A (ja)
AU (1) AU2019318070A1 (ja)
BR (1) BR112021001372A2 (ja)
CA (1) CA3107631A1 (ja)
EA (1) EA202190355A1 (ja)
IL (1) IL280382A (ja)
MX (1) MX2021001544A (ja)
SG (1) SG11202100834SA (ja)
WO (1) WO2020033537A1 (ja)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011268310A1 (en) * 2010-06-16 2013-01-10 Abbvie Inc. Comparison of protein samples
CN103299192B (zh) * 2010-09-21 2016-05-11 普罗蒂阿米克斯国际有限公司 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
JPWO2012111249A1 (ja) 2011-02-14 2014-07-03 学校法人麻布獣医学園 質量分析法における質量変化を検出する方法及び安定同位体標識タンパク質の絶対量の定量方法
WO2013151726A1 (en) * 2012-04-05 2013-10-10 Integrated Diagnostics, Inc. Srm methods in alzheimer's disease and neurological disease assays
MX2015006757A (es) * 2012-11-30 2015-11-30 Applied Proteomics Inc Método para la evaluación de la presencia de o riesgo de tumores de colon.
JP6416793B2 (ja) 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
EP2821076A1 (en) * 2013-07-02 2015-01-07 Stallergenes Sa C1q as a therapeutic agent of allergy and/or asthma
AU2015203904B2 (en) 2014-01-06 2018-07-19 Expression Pathology, Inc. SRM assay for PD-L1
WO2017026241A1 (ja) 2015-08-07 2017-02-16 国立大学法人愛媛大学 質量分析を用いたb型肝炎ウイルスの測定方法
KR20180067557A (ko) 2015-09-24 2018-06-20 익스프레션 패톨로지, 인크. 암 치료를 위한 Met 단백질의 정량화
EP3571222A4 (en) * 2017-01-19 2021-06-16 Cedars-Sinai Medical Center HIGHLY MULTIPLEXED MASS SPECTROMETRY-BASED PROCESSES ALLOWING THE MEASUREMENT OF 72 HUMAN PROTEINS
EP3521828A1 (en) 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema

Also Published As

Publication number Publication date
MX2021001544A (es) 2021-04-13
KR20210043589A (ko) 2021-04-21
AU2019318070A1 (en) 2021-02-18
US20230366888A1 (en) 2023-11-16
US11592449B2 (en) 2023-02-28
CN112888793A (zh) 2021-06-01
IL280382A (en) 2021-03-01
EA202190355A1 (ru) 2021-05-25
BR112021001372A2 (pt) 2021-05-04
CA3107631A1 (en) 2020-02-13
US20200064355A1 (en) 2020-02-27
EP3833775A1 (en) 2021-06-16
JP2021532360A (ja) 2021-11-25
JP2024032761A (ja) 2024-03-12
WO2020033537A1 (en) 2020-02-13
JP7419340B2 (ja) 2024-01-22

Similar Documents

Publication Publication Date Title
EP3134546A4 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP3283882A4 (en) BLOOD-BASED BIOMARKERS OF TUMOR SENSITIVITY AGAINST PD-1 ANTAGONISTS
DK3837330T3 (en) Use of refrigerant composition
EP3175242A4 (en) Quantifying monoclonal antibody therapeutics by lc-ms/ms
EP3149207A4 (en) Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response
IL268731A (en) New uses of anti-SIRPG antibodies
SG11202007966UA (en) Therapeutic uses of glp1r agonists
EP3190416A4 (en) Biomarker for predicting sensitivity to protein kinase inhibitor and use thereof
EP3606507A4 (en) SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER
IL270717A (en) Biomarkers for the diagnosis of lung cancer
GB201719639D0 (en) Setection of biomarkers
GB201607393D0 (en) Biomarkers for early diagnosis of ovarian cancer
EP3353292A4 (en) USE OF SERINE PROTEASE TO ENHANCE ETHANOL YIELD
EP3746791C0 (en) USE OF BMMF REP PROTEIN AS A BIOMARKER FOR COLON CANCER
SG11202011369VA (en) Blood biomarkers of stroke
GB201906176D0 (en) Gating of radiotherepy
EP3635402A4 (en) DISEASE BIOMARKER
IL280382A (en) Using liquid chromatography-mass spectrometry/mass spectrometry to quantify protein biomarkers
GB2575067B (en) Selection of identifiers
EP4083627A4 (en) PROGNOSTIC BIOMARKER OF CANCER
IL276107A (en) Crystalline forms of psoorstam
GB201907550D0 (en) Detection of biomarkers
IL274700A (en) Methods of assaying tropolone
EP3745856A4 (en) PROCEDURE FOR SUPERCOOLING AQUEOUS SAMPLES
GB201715511D0 (en) Predictive biomarker of AKI